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Prospective costing was carried out on the same sample of patients used in the effectiveness analysis.
Study sample
The authors did not state whether power calculations were performed. Patients 60 years and older were approached during their hospital stay; those who agreed to participate were screened for symptoms of depression, anxiety, or alcohol abuse. Thus, the sample appears to have been appropriate for the clinical study question. 5,463 patients were identified and 2,779 declined screening; patients declining consent were most likely to be African American, unemployed and older. A total of 1,687 were screened as eligible for treatment. Of these, 814 patients were randomised to UPBEAT and 873 were assigned to normal care. Ineligible patients were slightly older, had higher incomes and lower education levels than eligible patients.
Study design
The study was a randomised controlled trial but the authors did not state the method of randomisation. The study was carried out at 9 centres in the USA. Patients were followed up for 6, 12, and 24 months. The authors did not state whether patients were lost to follow-up and did not report any methods used to mask health care professionals responsible for care, patients or trial research staff to treatment allocation.
Analysis of effectiveness
The authors did not state whether the analysis was based on intention to treat analysis or on treatment completers only. The clinical outcomes of the study were as follows: Except for ethnicity, there were no statistically significant differences in demographic characteristics between the two groups of patients. The distributions of patients with various combinations of anxiety, depression, and alcohol abuse were similar for both treatment groups.
Effectiveness results
The effectiveness results were as follows:
MHI Anxiety and depression scores improved from baseline to 12 months in the UPBEAT group (18.5 to 15.6 and 8.1 to 7.0, respectively) and the usual care group (18.4 to 15.5 and 8.1 to 7.1, respectively); there were no statistically significant differences between UPBEAT and usual care. There were no statistically significant differences between the two groups on any of these outcome measures.
There were no statistically significant differences between the two groups in mortality at 12 months.
Clinical conclusions
Mental health and general health status scores improved equally from baseline to 12-month follow-up in the UPBEAT and usual care groups.
Measure of benefits used in the economic analysis
The outcomes were reported in a disaggregated way and as such the study is a cost-consequences analysis.
Direct costs
The resource quantities and costs were reported separately. Direct costs to the hospital were reported. The direct costs included in the analysis were:
Inpatient services (includes bed days of inpatient care in various specialities).
Outpatient services (included all ambulatory services for a single ambulatory care visit).
Visits were defined as unique days in which patients incurred one or more clinic stops. The costs were obtained from a national average cost per service calculated from the VA Cost Distribution Report (published 1999). National average costs were used to control for site-specific differences in per unit costs. Inpatient costs were obtained by multiplying each patient's bed days of care by the relevant cost per day. Outpatient costs were estimated by multiplying the number of clinic stops by the cost per clinic. Discounting was not carried out but was not relevant to the timeframe of the study (12 months).
The authors used validated measures of mental health and general health status. However, they noted that the instruments used were not sensitive to change or improvements in the risk of relapse, which may differ between the two interventions. The patient groups were comparable at baseline on all measures except ethnicity. The authors used t-test to detect statistically significant differences in outcomes. The authors used a Bonferonni adjustment to take account of multiple comparisons.
Validity of estimate of measure of benefit
No summary measure of benefit was defined in this study. No measure of the value of health states or outcomes of the interventions was used.
Validity of estimate of costs
Hospital inpatient and outpatient resource use data were collected for all patients enrolled in the study. The authors stated that national average costs were used to control for site-specific differences in per unit costs. Bivariate and multivariate analysis was used to analyse resource use and cost data, controlling for pre-enrolment hospital use. The costs of outpatient pharmaceutical therapy or care provided outside the Veterans Administration (VA) system were not included due to difficulties and high costs of obtaining the data. The authors noted that this might be an important limitation to the study. As depression and anxiety can be effectively managed with appropriate medication, these costs are important and pharmaceutical use may have increased among UPBEAT patients. In addition, elderly patients will receive a significant amount of care from non VA sources. Some additional costs of the UPBEAT programme (e.g. improved access to legal care, home services) were borne directly by the study participants.
